Susannah Friemel, MD
Hematology & Oncology · Davenport, IANPI 1356352116
Payments from drug & device makers
Across 662 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Novartis$2K
- Karyopharm Therapeutics Inc.$2K
- Athenex Pharmaceutical Division, LLC$1K
- Daiichi Sankyo Inc.$797
- Johnson & Johnson$741
- plus $8K from 54 others
What the payments were for
- Consulting fees$4,50023%
- Speaking & faculty fees$2,45012%
- Food & beverage$11,04656%
- Education$3482%
- Other$1,3817%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,725 in reported general payments places this provider in the 60th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 46 | $760,332 |
| AyvakitAvapritinib | 17 | $651,204 |
| ReblozylLuspatercept-Aamt | 41 | $593,356 |
| KisqaliRibociclib Succinate | 32 | $491,655 |
| Somatuline DepotLanreotide Acetate | 56 | $485,930 |
| RevlimidLenalidomide | 28 | $483,227 |
| PomalystPomalidomide | 21 | $462,099 |
| IbrancePalbociclib | 18 | $282,897 |
| IclusigPonatinib Hcl | 13 | $271,861 |
| XalkoriCrizotinib | 11 | $251,633 |
| NubeqaDarolutamide | 16 | $218,896 |
| PromactaEltrombopag Olamine | 16 | $210,854 |
| AlecensaAlectinib Hcl | 11 | $201,787 |
| Lenalidomide | 13 | $188,840 |
| AranespDarbepoetin Alfa In Polysorbat | 95 | $187,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Reblozyl, Pomalyst, Opdivo | $253 | $1,222,76984 claims |
| Incyte CorporationJakafi | $173 | $760,33246 claims |
| NovartisKisqali, Promacta | $2,377 | $702,51048 claims |
| Blueprint Medicines CorporationAyvakit | $99 | $651,20417 claims |
| PfizerIbrance, Xalkori, Eliquis | $4,871 | $579,06788 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $120 | $485,93056 claims |
| Bristol Myers SquibbRevlimid | $369 | $483,22728 claims |
| AmgenAranesp, Xgeva, Prolia | $643 | $356,224165 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $171 | $271,86113 claims |
| BayerNubeqa | $146 | $218,89616 claims |
| Genentech USA, Inc.Alecensa | $480 | $201,78711 claims |
| AstraZenecaLynparza | $692 | $183,87217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Davenport
- David MercerDavenport$13K
- George KovachDavenport$8K
- Umang SwamiIowa City$9.7M
- Mohammed MilhemIowa City$6.4M
- Umar FarooqIowa City$4.4M
- Varun MongaIowa City$3.6M
- Douglas LauxIowa City$3.3M
- Christopher StrouseIowa City$2.3M
- Mark KarwalIowa City$2M
- Donald WenderSioux City$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.